论文部分内容阅读
GH能促进细胞有丝分裂而可能使恶性细胞系重新激活。因此,对继发于脑瘤直接损害下丘脑—垂体区域或头颅放疗而致GH缺乏的儿童是否该用GH治疗的问题仍有争议。为此,作者研究了GH缺乏的24例脑瘤(14例成神经管细胞瘤、8例神经胶质瘤和2例室管膜瘤)、6例急性淋巴细胞白血病及1例T淋巴细胞瘤患者用GH治疗后的复发率,并与1972～1982年全部同类患者的复发率进行比较,以期作出正确回答。这些患者的GH缺乏均由头颅放疗所致,身高速率<10％,胰岛素耐量试验的GH峰值<15mu/I。GH治疗剂量为4IU,每周三次,平均开始于放疗后5.8年(范围1.2～10.9年)。复发是通过临床、放射检查或尸检而发现的。
GH promotes cell mitosis and may reactivate malignant cell lines. Therefore, it is still controversial whether the children who suffer from GH deficiency due to brain tumors directly impairing the hypothalamic-pituitary region or cranial radiotherapy should be treated with GH. To this end, the authors studied 24 brain tumors (14 medulloblastomas, 8 gliomas, and 2 ependymomas) with GH deficiency, 6 acute lymphoblastic leukemias, and 1 T-lymphocyte tumor. The recurrence rate after treatment with GH was compared with the recurrence rate of all patients in the same category from 1972 to 1982 in order to make a correct answer. The GH deficiency in these patients was caused by cranial radiotherapy, with a height rate of <10% and a peak GH of <15 mu/I in the insulin tolerance test. The GH treatment dose was 4 IU, three times per week, with an average of 5.8 years after radiotherapy (range 1.2 to 10.9 years). Recurrences are found through clinical, radiological or autopsy.